Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report

Published: June 30, 2017 Report Code: GDPH0511AD-ST

Select Item

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five years.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Pharmaceutical & Healthcare, Global, Deals Summary 13

2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2016 13

2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2016 by Quarter 14

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2016 16

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2016 17

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2016 18

2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2016 18

2.5.1 Bayer to Acquire Monsanto for USD66 Billion 18

2.5.2 Shire Acquires Baxalta for USD32 Billion 19

2.5.3 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 20

2.5.4 Teva Pharma Raises USD15 Billion in Public Offering of Notes 20

2.5.5 Pfizer Acquires Medivation in Tender Offer 20

2.5.6 Shire Raises USD12.1 Billion in Public Offering of Notes 21

2.5.7 Mylan Acquires Meda for USD9.9 Billion 22

2.5.8 AbbVie Acquires Stemcentrx 22

2.5.9 AbbVie to Raise USD7.8 Billion in Public Offering of Notes 23

2.5.10 Pfizer Raises USD6 Billion in Public Offering of Notes 23

3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2016 24

4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 25

4.1 Pharmaceuticals & Healthcare, Global, M&A, 2016 25

4.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2016 by Quarter 26

4.1.2 Top M&A Deals in 2016 27

4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2016 28

4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2016 29

4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2016 by Quarter 30

4.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2016 31

4.2.3 Top IPOs in 2016 32

4.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2016 32

4.2.5 Top Secondary Offerings in 2016 33

4.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2016 34

4.2.7 Top PIPE Deals in 2016 35

4.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2016 35

4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2016 36

4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2016 by Quarter 37

4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2016 38

4.3.3 Top Public Debt Offerings in 2016 39

4.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2016 39

4.3.5 Top Private Debt Placements in 2016 41

4.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2016 41

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2016 42

4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2016 by Quarter 43

4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2016 45

4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2016 46

4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 47

4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2016 48

4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2016 48

4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 50

4.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2016 51

4.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2016 52

4.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2016 52

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2016 53

4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2016 by Quarter 54

4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2016 54

4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2016 56

4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 57

4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2016 58

4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2016 59

4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 61

4.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2016 62

4.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2016 63

4.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2016 63

4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2016 64

4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2016 by Quarter 64

4.6.2 Top Private Equity Deals in 2016 66

4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2016 66

4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2016 68

4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2016 by Quarter 69

4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2016 70

4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2016 70

4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2016 71

4.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 72

4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2016 73

4.7.7 Top Venture Financing Deals in 2016 75

5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 76

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2016 76

5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2016 by Quarter 77

5.1.2 Oncology – Deals of the Year 78

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2016 82

5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2016 by Quarter 83

5.2.2 Central Nervous System – Deals of the Year 84

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2016 87

5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2016 by Quarter 89

5.3.2 Infectious Disease – Deals of the Year 90

5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2016 92

5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2016 by Quarter 94

5.4.2 Immunology – Deals of the Year 95

5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2016 97

5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2016 by Quarter 98

5.5.2 Cardiovascular – Deals of the Year 99

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2016 101

5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2016 by Quarter 103

5.6.2 Metabolic Disorders – Deals of the Year 104

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2016 106

5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2016 by Quarter 107

5.7.2 Gastrointestinal – Deals of the Year 109

6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 112

6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2016 112

6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2016 by Quarter 113

6.1.2 North America – Deals of the Year 114

6.2 Pharmaceuticals & Healthcare, European Region Deals, 2016 118

6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2016 by Quarter 119

6.2.2 Europe – Deals of the Year 120

6.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2016 124

6.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2016 by Quarter 125

6.3.2 Asia-Pacific – Deals of the Year 126

6.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2016 129

6.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2016 by Quarter 130

6.4.2 Rest of the World – Deals of the Year 131

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 133

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2016 133

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2016 134

8 Further Information 136

8.1 Methodology 136

8.2 About GlobalData 137

8.3 Contact Us 137

8.4 Disclosure information 137

8.5 Disclaimer 138

Table

1.1 List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 14

Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 15

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2016 17

Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2016 18

Table 5: Pharmaceuticals & Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (US$ m), 2016 24

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 26

Table 7: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 27

Table 8: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2016 27

Table 9: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2016 28

Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 29

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 30

Table 12: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 31

Table 13 Pharmaceuticals & Healthcare, Global, Top IPOs, 2016 32

Table 14: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 33

Table 15: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2016 33

Table 16: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 34

Table 17: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2016 35

Table 18: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 36

Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 37

Table 20: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 38

Table 21: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 39

Table 22: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2016 39

Table 23: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 40

Table 24: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2016 41

Table 25: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2016 42

Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2012 – 2016 43

Table 27: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016–Q4 2016 44

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 45

Table 29: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2016 46

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2016 47

Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2016 49

Table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2016 51

Table 33: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2016 51

Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2016 52

Table 35: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2016 52

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 53

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016–Q4 2016 54

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 55

Table 39: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2016 56

Table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2016 57

Table 41: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015 – Q4 2016 60

Table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 62

Table 43: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2016 62

Table 44: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2016 63

Table 45: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2016 63

Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 64

Table 47: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 65

Table 48: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2016 66

Table 49: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 67

Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 68

Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 69

Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2016 71

Table 53: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 72

Table 54: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2016 72

Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2016 74

Table 56: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2016 75

Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 77

Table 58: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 78

Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 83

Table 60: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 84

Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 88

Table 62: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 89

Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 93

Table 64: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 95

Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 98

Table 66: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 99

Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 102

Table 68: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 103

Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 107

Table 70: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 108

Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 113

Table 72: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2016–Q4 2016 114

Table 73: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 119

Table 74: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 120

Table 75: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 125

Table 76: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 126

Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 – 2016 130

Table 78: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2016–Q4 2016 131

Table 79: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2016 134

Table 80: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2016 135

Figures

1.2 List of Figures

Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2012- 2016 13

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 14

Figure 3: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 2016 16

Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2016 17

Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2012 – 2016 25

Figure 6 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 26

Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2016 28

Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2012 – 2016 29

Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 30

Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2012 – 2016 31

Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2012 – 2016 32

Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2012 – 2016 34

Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 35

Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2012 – 2016 36

Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 37

Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2012 – 2016 38

Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2012 – 2016 40

Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 41

Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2012 – 2016 42

Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 43

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2016 44

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 45

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2016 46

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2016 47

Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2016 48

Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2016 48

Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 50

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2012 – 2016 53

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 54

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 55

Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2016 56

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2016 57

Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2016 58

Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2016 59

Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2016 61

Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2012 – 2016 64

Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 65

Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2016 66

Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2012 – 2016 68

Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 69

Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2016 70

Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2016 70

Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2016 71

Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2016 73

Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2012 – 2016 76

Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 77

Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2016, 2012 – 2016 82

Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 83

Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2012 – 2016 87

Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 89

Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2012 – 2016 92

Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 94

Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2012 – 2016 97

Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 98

Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2012 – 2016 101

Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 103

Figure 57: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 – 2016 106

Figure 58: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 108

Figure 59: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2012 – 2016 112

Figure 60: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2016–Q4 2016 113

Figure 61: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2012 – 2016 118

Figure 62: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2016–Q4 2016 119

Figure 63: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2012 – 2016 124

Figure 64: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2016–Q4 2016 125

Figure 65: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2012 – 2016 129

Figure 66: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2016–Q4 2016 130

Figure 67: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2016 133

Figure 68: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2016 134

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals standard reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more